We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Roche Launches Software Upgrade for GS Junior System

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Roche has announced the immediate availability of a new software upgrade and further upcoming sequencing performance and workflow improvements to the company’s 454 GS Junior System.

Now a widely published benchtop next-generation sequencing platform, the GS Junior System is rapidly advancing research worldwide in areas of infectious disease, cancer, environmental microbiology and agriculture.

The new software package (v2.7) improves sequencing consistency and robustness and also includes functionality improvements to the GS De Novo Assembler, GS Reference Mapper, and GS Amplicon Variant Analyzer Software.

The company also announced the immediate availability of new protocols for paired end sequencing (3 kb, 8 kb, 20 kb span) using the GS FLX Titanium Rapid Library Preparation Kits.

The protocols enable simple sample multiplexing for paired end projects and reduce overall prep time.

In addition, the company has announced upcoming improvements to the GS Junior System, which include extension to sequencing read lengths and automation of the library preparation and emPCR workflow.

The improvements will further ease the transition of projects from traditional Sanger capillary sequencing to 454 Sequencing Systems in basic and translational research laboratories around the world.

The planned improvements will first become available in late 2012 and during 2013.

“We are pleased by the adoption of the GS Junior System worldwide and are excited to announce our efforts to continuously improve performance and ease of use of the platform,” said Thomas Schinecker, President of 454 Life Sciences, a Roche Company.

Schinecker continued, “These improvements make our long read sequencing solution more user friendly and enable customers to convert projects from Sanger to next-generation sequencing more easily.”